KEMP PROTEINS, LLC

KEMP PROTEINS, LLC specializes in the research, development, and manufacturing of biological products through advanced protein expression systems, with a focused expertise in baculovirus-based platforms. The company delivers end-to-end biotechnological services including recombinant protein production, cell culture optimization, and laboratory testing for complex biological materials. Their technical capabilities center on eukaryotic expression systems, particularly insect cell-derived protein purification and characterization, supporting preclinical and therapeutic development pipelines. A key differentiator is their proven proficiency in scaling baculovirus-mediated expression for high-yield, post-translationally modified proteins—critical for vaccine candidates and biologics requiring native folding and glycosylation patterns. Their work aligns with stringent regulatory standards for biological manufacturing, demonstrating deep familiarity with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) environments. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering specialized research and manufacturing services primarily to agencies under the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases. Their engagements involve mission-critical support for infectious disease and therapeutic protein development, indicating a trusted role in advancing federal biomedical research initiatives. KEMP PROTEINS, LLC operates primarily under NAICS 541714 for biotechnology R&D and 325414 for biological product manufacturing, positioning them as a niche provider bridging discovery and production in the biopharmaceutical lifecycle. They serve the federal biodefense, vaccine development, and therapeutic protein markets with precision-focused capabilities. As a small business structured as a 2K entity based in Frederick, Maryland, the company is privately held with no federal certifications on record. Their geographic presence is centered in the Mid-Atlantic biotech corridor, leveraging proximity to federal research institutions and bioscience infrastructure to support mission-driven government contracts.